Top Markets
#1 Cross Cross +16.09%
#2 Glidr Glidr +10.10%
#3 Gama Token Gama Token +8.43%
#4 TDCCP TDCCP +4.76%
#5 Akedo Akedo +4.66%
#6 龙虾 (Lobster) 龙虾 (Lobster) +4.64%
#7 LEO Token LEO Token +4.36%
#8 Pieverse Pieverse +4.24%
#9 Humanity Humanity +4.09%
#10 Berachain Berachain +3.39%
Coin of the day
Cross Cross
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Guard Therapeutics International AB (publ) Guard Therapeutics International AB (publ)

Guard Therapeutics International AB (publ)

GUARD
Rang in aandelen #36113
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company... Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
Aandeelprijs
$0.14966934
Laatst gesynchroniseerd: 2026-08-14
Marktkapitalisatie
$3.02M
Verandering (1 dag)
3.72%
Verandering (1 jaar)
-93.70%
Land
SE
Handel Guard Therapeutics International AB (publ) (GUARD)

Categorie

Healthcare
Winst voor Guard Therapeutics International AB (publ) (GUARD)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Guard Therapeutics International AB (publ) bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Guard Therapeutics International AB (publ) van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE